Company Encyclopedia
View More
name
Inhibikase Therapeutics
IKT.US
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.
1.946 T
IKT.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    FY2025 Earnings Estimate for IKT Issued By Lifesci Capital

    Lifesci Capital issued FY2025 EPS estimates for Inhibikase Therapeutics, predicting earnings of ($0.57) per share. The consensus estimate for current full-year earnings is ($0.97) per share. Lifesci also provided estimates for future years, with FY2026 at ($1.00) EPS and FY2029 at ($1.00) EPS. Inhibikase stock is trading down 6.0%, with a market cap of $106 million. Institutional investors have adjusted their stakes in the company. Inhibikase develops therapeutics for Parkinson's disease, with its lead product in Phase 2a trials.

    Market Beat·
    US
    IKT
    +4.86%
    Market Beat·
    US
    IKT
    +4.86%

    Sands Capital Life Sciences Pulse Fund II Reports Acquisition of Inhibikase Therapeutics Common Shares

    Sands Capital Life Sciences Pulse Fund II, L.P. has acquired common shares of Inhibikase Therapeutics Inc. (IKT), as reported in a recent regulatory filing. The filing was submitted by Sands Capital Life Sciences Pulse Fund II, L.P. and other beneficial owners. This information was originally published by Inhibikase Therapeutics Inc. via the EDGAR system of the U.S. Securities and Exchange Commission.

    Reuters·
    US
    IKT
    +4.86%
    Reuters·
    US
    IKT
    +4.86%

    Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share

    Inhibikase Therapeutics Inc :INHIBIKASE THERAPEUTICS ANNOUNCES PRICING OF $100 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTSINHIBIKASE THERAPEUTICS INC - PRICES PUBLIC OFFERING OF 46 MILLION SHARES AT $1.45 PER SHARE

    Reuters·
    US
    IKT
    +4.86%
    Reuters·
    US
    IKT
    +4.86%

    Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

    BOSTON and ATLANTA, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Inhibikase Therapeutics, Inc. ( NASDAQ: IKT ) ( "Inhibikase" or "Company" ) , a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension ( "PAH" ) , today announced that it has ...

    GlobeNewswire·
    US
    IKT
    +4.86%
    GlobeNewswire·
    US
    IKT
    +4.86%

    Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension

    Inhibikase Therapeutics Inc :INHIBIKASE THERAPEUTICS ADVANCING IKT-001 TO GLOBAL PHASE 3 STUDY IN PULMONARY ARTERIAL HYPERTENSIONINHIBIKASE THERAPEUTICS INC - IMPROVE-PAH PHASE 3 STUDY EXPECTED TO START IN Q1 2026

    Reuters·
    US
    IKT
    +4.86%
    Reuters·
    US
    IKT
    +4.86%
    © 2025 Longbridge｜Disclaimer